Effects of 12 weeks of probiotic supplementation on quality of life in colorectal cancer survivors

A double-blind, randomized, placebo-controlled trial

Jee Yon Lee, Sang Hui Chu, Justin Y. Jeon, Mi Kyung Lee, Ji Hye Park, Duk Chul Lee, Ji Won Lee, Namkyu Kim

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background: Probiotics may help resolve bowel symptoms and improve quality of life. We investigated the effects of 12 weeks of probiotics administration in colorectal cancer patients. Methods: We conducted a double-blind, randomized, placebo-controlled trial. The participants took probiotics (Lacidofil) or placebo twice a day for 12 weeks. The cancer-related quality of life (FACT), patient's health-9 (PHQ-9), and bowel symptom questionnaires were completed by each participant. Results: We obtained data for 32 participants in the placebo group and 28 participants in the probiotics group. The mean ages of total participants were 56.18 ± 8.86 years and 58.3% were male. Administration of probiotics significantly decreased the proportion of patients suffering from irritable bowel symptoms (0 week vs. 12 week; 67.9% vs. 45.7%, p = 0.03), improved colorectal cancer-related FACT (baseline vs. 12 weeks: 19.79 ± 4.66 vs. 21.18 ± 3.67, p = 0.04) and fatigue-related FACT (baseline vs. 12 weeks: 43.00 (36.50-45.50) vs. 44.50 (38.50-49.00), p = 0.02) and PHQ-9 scores (0 weeks vs. 12 weeks; 3.00 (0-8.00) vs. 1.00 (0-3.00), p = 0.01). We found significant differences in changes of the proportion of patients with bowel symptoms (p < 0.05), functional well-being scores (p = 0.04) and cancer-related FACT scores (p = 0.04) between the two groups. Conclusion: Probiotics improved bowel symptoms and quality of life in colorectal cancer survivors.

Original languageEnglish
Pages (from-to)1126-1132
Number of pages7
JournalDigestive and Liver Disease
Volume46
Issue number12
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Probiotics
Survivors
Colorectal Neoplasms
Randomized Controlled Trials
Placebos
Quality of Life
Fatigue
Neoplasms
Health

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

@article{b4b88110f19e445e93f819ae5026819e,
title = "Effects of 12 weeks of probiotic supplementation on quality of life in colorectal cancer survivors: A double-blind, randomized, placebo-controlled trial",
abstract = "Background: Probiotics may help resolve bowel symptoms and improve quality of life. We investigated the effects of 12 weeks of probiotics administration in colorectal cancer patients. Methods: We conducted a double-blind, randomized, placebo-controlled trial. The participants took probiotics (Lacidofil) or placebo twice a day for 12 weeks. The cancer-related quality of life (FACT), patient's health-9 (PHQ-9), and bowel symptom questionnaires were completed by each participant. Results: We obtained data for 32 participants in the placebo group and 28 participants in the probiotics group. The mean ages of total participants were 56.18 ± 8.86 years and 58.3{\%} were male. Administration of probiotics significantly decreased the proportion of patients suffering from irritable bowel symptoms (0 week vs. 12 week; 67.9{\%} vs. 45.7{\%}, p = 0.03), improved colorectal cancer-related FACT (baseline vs. 12 weeks: 19.79 ± 4.66 vs. 21.18 ± 3.67, p = 0.04) and fatigue-related FACT (baseline vs. 12 weeks: 43.00 (36.50-45.50) vs. 44.50 (38.50-49.00), p = 0.02) and PHQ-9 scores (0 weeks vs. 12 weeks; 3.00 (0-8.00) vs. 1.00 (0-3.00), p = 0.01). We found significant differences in changes of the proportion of patients with bowel symptoms (p < 0.05), functional well-being scores (p = 0.04) and cancer-related FACT scores (p = 0.04) between the two groups. Conclusion: Probiotics improved bowel symptoms and quality of life in colorectal cancer survivors.",
author = "Lee, {Jee Yon} and Chu, {Sang Hui} and Jeon, {Justin Y.} and Lee, {Mi Kyung} and Park, {Ji Hye} and Lee, {Duk Chul} and Lee, {Ji Won} and Namkyu Kim",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.dld.2014.09.004",
language = "English",
volume = "46",
pages = "1126--1132",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier",
number = "12",

}

Effects of 12 weeks of probiotic supplementation on quality of life in colorectal cancer survivors : A double-blind, randomized, placebo-controlled trial. / Lee, Jee Yon; Chu, Sang Hui; Jeon, Justin Y.; Lee, Mi Kyung; Park, Ji Hye; Lee, Duk Chul; Lee, Ji Won; Kim, Namkyu.

In: Digestive and Liver Disease, Vol. 46, No. 12, 01.01.2014, p. 1126-1132.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of 12 weeks of probiotic supplementation on quality of life in colorectal cancer survivors

T2 - A double-blind, randomized, placebo-controlled trial

AU - Lee, Jee Yon

AU - Chu, Sang Hui

AU - Jeon, Justin Y.

AU - Lee, Mi Kyung

AU - Park, Ji Hye

AU - Lee, Duk Chul

AU - Lee, Ji Won

AU - Kim, Namkyu

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: Probiotics may help resolve bowel symptoms and improve quality of life. We investigated the effects of 12 weeks of probiotics administration in colorectal cancer patients. Methods: We conducted a double-blind, randomized, placebo-controlled trial. The participants took probiotics (Lacidofil) or placebo twice a day for 12 weeks. The cancer-related quality of life (FACT), patient's health-9 (PHQ-9), and bowel symptom questionnaires were completed by each participant. Results: We obtained data for 32 participants in the placebo group and 28 participants in the probiotics group. The mean ages of total participants were 56.18 ± 8.86 years and 58.3% were male. Administration of probiotics significantly decreased the proportion of patients suffering from irritable bowel symptoms (0 week vs. 12 week; 67.9% vs. 45.7%, p = 0.03), improved colorectal cancer-related FACT (baseline vs. 12 weeks: 19.79 ± 4.66 vs. 21.18 ± 3.67, p = 0.04) and fatigue-related FACT (baseline vs. 12 weeks: 43.00 (36.50-45.50) vs. 44.50 (38.50-49.00), p = 0.02) and PHQ-9 scores (0 weeks vs. 12 weeks; 3.00 (0-8.00) vs. 1.00 (0-3.00), p = 0.01). We found significant differences in changes of the proportion of patients with bowel symptoms (p < 0.05), functional well-being scores (p = 0.04) and cancer-related FACT scores (p = 0.04) between the two groups. Conclusion: Probiotics improved bowel symptoms and quality of life in colorectal cancer survivors.

AB - Background: Probiotics may help resolve bowel symptoms and improve quality of life. We investigated the effects of 12 weeks of probiotics administration in colorectal cancer patients. Methods: We conducted a double-blind, randomized, placebo-controlled trial. The participants took probiotics (Lacidofil) or placebo twice a day for 12 weeks. The cancer-related quality of life (FACT), patient's health-9 (PHQ-9), and bowel symptom questionnaires were completed by each participant. Results: We obtained data for 32 participants in the placebo group and 28 participants in the probiotics group. The mean ages of total participants were 56.18 ± 8.86 years and 58.3% were male. Administration of probiotics significantly decreased the proportion of patients suffering from irritable bowel symptoms (0 week vs. 12 week; 67.9% vs. 45.7%, p = 0.03), improved colorectal cancer-related FACT (baseline vs. 12 weeks: 19.79 ± 4.66 vs. 21.18 ± 3.67, p = 0.04) and fatigue-related FACT (baseline vs. 12 weeks: 43.00 (36.50-45.50) vs. 44.50 (38.50-49.00), p = 0.02) and PHQ-9 scores (0 weeks vs. 12 weeks; 3.00 (0-8.00) vs. 1.00 (0-3.00), p = 0.01). We found significant differences in changes of the proportion of patients with bowel symptoms (p < 0.05), functional well-being scores (p = 0.04) and cancer-related FACT scores (p = 0.04) between the two groups. Conclusion: Probiotics improved bowel symptoms and quality of life in colorectal cancer survivors.

UR - http://www.scopus.com/inward/record.url?scp=84930712312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930712312&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2014.09.004

DO - 10.1016/j.dld.2014.09.004

M3 - Article

VL - 46

SP - 1126

EP - 1132

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 12

ER -